Purpose: Chronic radiation enteritis (CRE) is one of the most feared complications of abdominal or pelvic radiation therapy and the treatment of CRE is di cult and o en controversial. Recent progress in molecular biology has shed some light on the pathogenesis of CRE, which is characterized by brosis. e purpose of this article is to summarize the current state of knowledge of molecular aspects of radiation induced intestinal brosis and to discuss potential therapeutic targets.
Chronic radiation enteritis (CRE) is an increasing clinical problem in patients receiving radiation directed at the abdomen or pelvis. e incidence of CRE reported in medical literature is as high as 20% [1] [2] [3] . Progressive damage to intestine and some predisposing factors (including a low body mass index, previous abdominal surgery and the presence of comorbid conditions, as well as the concomitant use of chemotherapy) can lead to various gastrointestinal symptoms, which severely a ect quality of life and are frequently poorly managed [4] [5] [6] . Despite improved techniques in radiation therapy, the percentage of patients exhibiting complications has not declined, likely because radiation therapy is increasingly being used following surgery or in association with chemotherapy. CRE is primarily characterized by intestinal brosis, and can be the underlying cause of stricture, obstruction, stula and perforations of the intestine.
e underlying mechanisms involved in development of intestinal brosis are still unclear; consequently, the medical and surgical treatment of CRE have o en been disappointing [7] [8] [9] . In this review, we summarize the pathology, possible molecular cascades and future perspective treatment of CRE, and discuss the potential therapeutic targets.
Pathology of CRE
Excess radiation can damage normal cells, especially the rapidly growing mucosal epithelial cells of the gastrointestinal tract.
e development of bowel toxicity is not entirely dose, volume and fractionation schedule related -it also depends on a complex interaction among physical, patient-related and genetic factors, such as body mass and previous abdominal surgery. It is now recognized that radiation-induced changes in cellular function, as well as secondary alterations, notably in ammatory changes, contribute substantially to the pathophysiologic manifestations of intestinal radiation toxicity. Oxidative damage, caused by the formation of free radicals, results in obliterative endarteritis leading to intestinal ischemia that may contribute to radiation injury. Ischemia can lead to di use brosis in the lamina propria and submucosa of the intestine. Subsequently, brosis, in turn, aggravates vascular damage and further worsens local ischemia. is persistent malignant cycle induces intestinal dysfunction and leads to severe gastrointestinal complications [10, 11] .
e cumulative e ects of these pathological changes might gradually result in vascular degeneration, mucosal ulceration, intestinal wall necrosis and serosal adhesion formation. e vasculitis and brosis progress over time, resulting in narrowing of the intestinal lumen with dilation of the bowel proximal to the stricture. e a ected segments of intestine and serosa become thickened. e main feature of intestinal brosis is the accumulation of extracellular matrix that induces the loss of intestinal compliance, impairs function, and leads to severe complications. Ulceration, obstruction, necrosis, stula, and occasional perforation of the intestine may occur. In a word, obliterative endarteritis, submucosal brosis, lymphatic dilatation and tissue necrosis are common features of CRE, while brosis is the most salient [1, 12] .
Current research on molecular pathogenesis of CRE
During the past few years, much progress has been made in elucidating the cellular mechanisms underlying CRE. e role of intestinal mesenchymal cells (myo broblasts, broblasts and smooth muscle cells) in intestinal brosis is increasingly recognized. In normal bowel, these cells are involved in the maintenance of intestinal contraction and extracellular matrix homeostasis. Once activated via radiation, their role is enhanced as they are responsible for excessive deposition of extracellular matrix components and collagen, gradually leading to intestinal dysfunction. Compared with normal human smooth muscle cells, cells derived from radiation enteropathy displayed a speci c radiation-induced brogenic di erentiation with an altered cytoskeleton structure and prosecretory phenotype. In addition, similar features were observed in broblasts and myo broblasts, which might re ect that common pathways maintain radiation-induced brogenic di erentiation in intestinal mesenchymal cells. Chronic cellular activation within the mesenchymal compartment is one of the key mechanisms involved in radiation induced brosis (RIF) [13, 14] .
Research on the molecular actors involved in the radiation-induced brogenic di erentiation has mostly focused on one signi cant brogenic growth factor, transforming growth factor β1 (TGF-β1) [15] . TGF-β1 is a multifunctional cytokine that regulates homeostasis in various cell types, including epithelial and endothelial cells, and regulates other cell functions, such as growth, di erentiation and apoptosis. It exerts its biological e ects through a variety of signaling pathways of which receptor-regulated Smad signaling is considered to be the main mediator. Brie y, TGF-β1 initiates its cellular response by binding to its speci c receptor, TGF-β receptor II (TβRII). A er ligand binding, TβRII activates TβRI kinase, which phosphorylates RSmads (Smad2 and Smad3). Activated Smads assemble with Smad4 and translocate into the nucleus where they bind to promoters and regulate the expression of various target genes involved in brosis. Connective tissue growth factor (CTGF) is the main downstream mediator of TGF-β1-induced activation of broblasts, and it is highly expressed in sub-acute and delayed radiation injury of the ileum Zhu et al. Fibrosis of chronic radiation enteritis and colon. One hallmark of radiation-induced brogenic phenotype of intestinal smooth muscle cells is the high constitutive levels of CTGF [16] [17] [18] . It is believed that brosis is correlated with TGF-β1 gene polymorphism and activation of the TGF-β1/Smad pathway, which stimulates brogenic downstream mediators, such as CTGF, and deposition of extracellular matrix. Understanding the cooperation between TGF-β1 and CTGF, is critical to our overall understanding of brosis development and maintenance [19, 20] .
Haydont and colleagues reported that nuclear accumulation of Smads in human smooth muscle cells, isolated from radiation enteritis (RE-SMC) treated with TGF-β1, was lower than in TGF-β1-treated human smooth muscle cells isolated from normal (N-SMC). Smad DNA-binding activity was also weaker in RE-SMC than N-SMC, suggesting the involvement of another signaling pathway in CTGF regulation. ey found that nuclear accumulation of Rho, as well as their DNAbinding activity, was higher in RE-SMC than in N-SMC, suggesting a strong involvement of the Rho pathway in sustained brogenic di erentiation [21] . Ras homologue (Rho) family small G proteins control many aspects of cell proliferation, including cell-cycle progression and cytokinesis, by acting as molecular switches, c cycling between active (GTP-bound) and inactive (GDP-bound) states. Active GTPases interact with high a nity with one of several downstream e ectors to modulate their activity and localization, including the Rho-associated kinase (ROCK). e small GTPases Rho and ROCK play important roles in gra brosis; it is now generally considered to be a major factor in the progression of chronic renal diseases, but their speci c mechanisms are still unknown. Researches have demonstrated that Rho and ROCK play a key role in intestinal brogenesis, including formation of CTGF and type I collagen in smooth muscle cells derived from the intestine. Although the precise mechanism has yet to be determined, several lines of evidence point to its e ect on cytoskeletal organization as well as its ability to modulate CTGF gene expression that suggest that the Rho signaling pathway is involved in the brogenic di erentiation of intestinal mesenchymal cells. Considered together, Rho and ROCK display potent brogenic activity, and targeting the Rho-kinase signaling network may be a useful treatment for intestinal RIF [22, 23] .
Recently, more attention has been paid to whether there is a crosstalk between these two signaling pathways. Vardouli and colleaguesdemonstrated that Rho signaling regulated TGF-β-induced rapid actin reorganization in Swiss 3T3 broblasts. In mouse Swiss3T3 broblasts and human hepatoma HepG2 cells, they reported that TGF-β regulated long-term actin remodeling by increasing the steady-state mRNA levels of the RhoB gene. Adenovirus-mediated gene transfer of Smad2 and Smad3 in Swiss 3T3 broblasts induced transcription of the endogenous RhoB gene but not the RhoA gene. In addition, Smad2 and Smad3 triggered activation of RhoA and RhoB GTPases and long-term actin reorganization in Swiss 3T3
broblasts. ey concluded that there was novel crosstalk between the classical TGF-β ⁄ Smad pathway and Rho GTPases, which might be involved in the broblast-myo broblast differentiation [24] . e relationship between the Smad and Rho pathways has not yet been elucidated (Figure 1 ).
Future perspective treatments
CRE continues to be a hazard.. Palliative surgical or medical interventions are the options of choice for the majority of CRE patients, but the results are disappointing [25] . In a prospective multicenter study, Larsen and colleagues demonstrated that at least 10% of patients with CRE die as a direct result of CRE and that most surviving patients su er from chronic debilitat-
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Clin In E121 ing symptoms that negatively in uence their quality of life for decades [26] . Radiation brosis was considered permanent and irreversible; however, this study of the cellular and molecular mechanisms involved in the persistence of human radiation enteropathy showed that severe brotic lesions are highly dynamic, and that biochemical maintenance of radiation brosis is a complex process that depends on continuous and integrated activation loops that involve cell di erentiation and cross-talk between the various cellular signaling pathways, providing new opportunities for the development of anti brotic therapies [1, 13, 24] .
Due to its central role in the development of brosis, TGF-β1 remains an attractive therapeutic target focusing on intestinal RIF. Soluble TßRII receptor, neutralizing antibodies, sequestering agents, and antisense therapy have shown to prevent RIF development in various experimental models. Nevertheless, in neoplastic disease, TGF-β acts as a tumor suppressor in early phases, but later it acts as a pro-metastatic agent: tumor cells could escape selectively from the growth inhibitory e ects of TGF-β, which then promotes metastasis. us, the e ects of TGF-β inhibitors with radiotherapy under tumor prone conditions are disputable [13, 17] .
e availability of small molecules, such as statins (Rho isoprenylation inhibition) and Y-27632 (allosteric inhibitor of ROCK), acting as inhibitors of Rho/ROCK/CTGF pathway, has recently made possible a more targeted anti-brotic approach to CRE. e pleiotropic actions of statins are mediated by inhibition of the production of isoprenoid residues and subsequent modulation of posttranslational protein prenylation, including that of Rho [27] . Preclinical studies suggest that pravastatin inhibited the Rho/ROCK/CTGF cascade in human samples ex vi o and showed decreased intestinal radiationinduced brosis in vi o [28, 29] . Pravastatin protects normal intestine from radiation damage without interfering with the anticancer action of irradiation in experimental models, both in vitro and in vi o. Other studies using simvastatin con rmed these results [30, 31] . Although additional mechanisms might be involved, such as endothelial barrier function, in ammation, platelet activation, thrombosis and oxidative stress, a highly signi cant observation using statins as Rho/ROCK inhibitors suggest possibilities for clinical intervention.
Researches have also reported that other molecules, including cyclooxygenase-2 inhibitor (rofecoxib), all-transretinoic acid, plasminogen activator inhibitor type-1 and γ-Tocotrienol, ameliorated irradiation-induced intestinal injury and brosis in animal models (Table 1 ) [32] [33] [34] [35] .
Radiation is genotoxic and induces DNA damage in human cells yet few researches have tried to identify regulators that in uence the expression levels of radiation-responsive genes. e genetic analysis of human gene expression might expand our understanding of gene regulation and have clinical implications. Despite the progress acquired with in vitro and animal models, the potential contribution of research based on human tissue samples has never been greater [36] [37] [38] [39] .
Additionally, hyperbaric oxygen, possibly through stimulation of angiogenesis, appeared to be e ective therapy for CRE. In a retrospective study, Marshall found that hyperbaric oxygen resulted in healing or clinically signi cant improvement in two thirds of patients with CRE [40] . Hyperbaric oxygen is apparently safe and e ective in managing radiation-induced late sidee ects, such as so tissue necrosis, proctitis and stulas [41] . Further multicenter investigation is warranted to con rm the e cacy of this treatment.
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Conclusion
Current treatment of patients with CRE is only supportive and, not surprisingly, is ine ective, because it is not based on a thorough understanding of the pathogenesis of the disease at the molecular level. e identi cation of key molecular targets involved in radiation-induced brosis could, in turn, provide e ective therapeutic targets. 
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